Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.
about
A low-carbohydrate, ketogenic diet to treat type 2 diabetes.Intensive glucose control versus conventional glucose control for type 1 diabetes mellitusGlycemic Targets in Diabetes Care: Emerging Clarity after AccordThe interplay of autoimmunity and insulin resistance in type 1 diabetesInsulin sensitivity and complications in type 1 diabetes: New insightsWeight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications TrialInsulin therapy and hypoglycemia.Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in BrazilReplacement of neutral protamine Hagedorn insulin with the long-acting insulin analogue, detemir, improves glycemic control without weight gain in basal-bolus insulin therapy in Japanese patients with type 1 diabetes.An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance.Effect of the carbohydrate counting method on glycemic control in patients with type 1 diabetesType 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association.Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.Obesity independently predicts responders to biphasic insulin 50/50 (Humalog Mix50 and Insuman Comb 50) following conversion from other insulin regimens: a retrospective cohort studyDiabetes management in the new millennium using insulin pump therapy.Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes.Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocin-induced diabetic mice.A decade of temporal trends in overweight/obesity in youth with type 1 diabetes after the Diabetes Control and Complications Trial.Serum lipid profiles and glycemic control in adolescents and young adults with type 1 diabetes mellitus.Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes.Temporal patterns in overweight and obesity in Type 1 diabetes.Progression to microalbuminuria in patients with type 1 diabetes: a seven-year prospective study.Obesity and coronary artery calcium in diabetes: the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study.Secular trends in growth in diabetes: are we winning?Improving Assessment of Lipoprotein Profile in Type 1 Diabetes by 1H NMR Spectroscopy.Overweight children with type 1 diabetes have a more favourable lipid profile than overweight non-diabetic children.Liraglutide for treating type 1 diabetes.Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.Insulin treatment and cardiovascular disease; friend or foe? A point of view.Association of insulin sensitivity to lipids across the lifespan in people with Type 1 diabetes.Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication.Energizing the mind and body.Optimal control of blood glucose: the diabetic patient or the machine?Safety and side effects of the insulin analogues.Challenges and strategies for moving patients to injectable medications.Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetesLong-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy.
P2860
Q21245078-FF677661-443E-4997-9388-6BDF18666260Q24200376-F68ABC0E-6FA0-4EB0-A342-44588A69B136Q26795380-F4772918-DB8F-4104-86E9-A3E866E1DDE9Q26823862-C04DD518-BF7C-4009-9D96-6028E2A7A317Q27000205-DC36A78C-A21A-41BB-8B49-99B2411A72A0Q27026774-5E063386-95B9-45AA-AE56-17E9FD39B0FFQ28360409-8ECAF284-9CBA-431C-8E75-8471BE2DF63DQ30409109-A2721D33-1291-4D0B-A2FE-206A18EDCF91Q30437086-A8ACA02A-958B-40EC-8EF9-BACC15930D0CQ30830573-63C7F30D-0907-4BD4-BE10-BC2830939E07Q33558415-6AC79DD5-3199-45CD-8E46-7914E2838C71Q33902616-042B746B-AE93-4384-9F4A-0D55981D3EACQ33930299-A726A183-9556-4146-B88C-9929D51C5B46Q34105067-C36A9134-8CCB-4F9F-A37A-BAAFF775D7C4Q34219439-D2DD6E76-6F6E-47F2-B5C2-5863F3963DB0Q34361001-C265EC4A-A481-4ADB-8CDB-CECCCDDA01F2Q34419149-8DE35180-8EEF-426A-9045-ADFD0DB026AEQ34580945-A6D61FC5-B9D8-495A-8CF5-C99CF24CA40BQ34663256-5CEB7773-DBDE-42C1-B2C8-2FC96641BAEDQ34734402-81F9BBD8-C527-4976-9DF5-E174D7C2CF69Q34921545-32F661D0-E334-4522-865D-2421CF992BACQ35046826-BB76B5B8-2876-41D5-990E-977A84BAC9C7Q35060243-0812CD27-4434-4998-AFB4-D71C2C735370Q35086491-DEB3A0A4-E2DB-4B3C-947B-1814CB9FE0B0Q35225575-9BDF9F7F-27B1-40B7-8E9E-832B8EAFF1C1Q35239509-72E6FEF1-0C9E-4D5A-983D-2163986902CDQ35275344-2BEF25A4-6BA9-4018-B1BE-154826FF1F54Q35759248-359ABDD2-BD5B-41F0-962F-6B503EAE3CF5Q35772433-BC0795ED-1E43-42D4-9211-90AC4C938986Q35939660-B8136FD6-FB9B-4E16-8213-D4D9BF5E474BQ36012965-442E16E4-075C-4169-AF29-7DB50D2D3815Q36014899-263FF971-A3E5-42B9-A0FC-F09019F0F8AFQ36091431-0A12A70D-9B72-4040-9442-3E349FCFF29BQ36117272-7D1BE24F-B49F-4938-A62F-3D95721C09B0Q36182465-62CB9CEB-3C12-4E17-9A03-53B15CC4B55EQ36206226-4D7146D9-3D1D-42E4-9F07-92FA7CEF10EFQ36349754-2B97C75D-7C38-4B43-A25D-5C3D2A5EA73AQ36428808-5D907550-7118-4B00-BAE5-0C77783432C7Q36494412-D24DAF58-41F2-4E3F-BDDF-D0AA56DE2BD3Q36527752-5E9FD6F4-DA00-4607-AF7D-3D85302666C2
P2860
Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 1998
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effect of excessive weight gai ...... ntrol and Complications Trial.
@en
Effect of excessive weight gai ...... ntrol and Complications Trial.
@nl
type
label
Effect of excessive weight gai ...... ntrol and Complications Trial.
@en
Effect of excessive weight gai ...... ntrol and Complications Trial.
@nl
prefLabel
Effect of excessive weight gai ...... ntrol and Complications Trial.
@en
Effect of excessive weight gai ...... ntrol and Complications Trial.
@nl
P2093
P2860
P356
P1476
Effect of excessive weight gai ...... ntrol and Complications Trial.
@en
P2093
J D Brunzell
J E Hokanson
J Q Purnell
M W Steffes
P A Cleary
S M Marcovina
P2860
P304
P356
10.1001/JAMA.280.2.140
P407
P577
1998-07-01T00:00:00Z